Treatment of lympho-proliferative disease with rituximab.
Niedermeyer
J
J
Hoffmeyer
F
F
Hertenstein
B
B
Hoeper
M M
MM
Fabel
H
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy; D016041:Heart-Lung Transplantation; D006566:Herpesviridae Infections / Q000188:drug therapy; D004854:Herpesvirus 4, Human; D006801:Humans; D016040:Lung Transplantation; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy* / Q000821:virology; D000069283:Rituximab; D014412:Tumor Virus Infections / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab